Waters Corporation delivered exactly what the market's more demanding expectations called for. Third-quarter adjusted EPS of $4.10 matched the Earnings Whisper number, topped the $3.99 consensus and the company's own $3.95-$4.05 guide, and grew 20.6% year over year. Revenue of $1.767 billion beat consensus by 1.0% and rose 120.9%, though that figure mostly reflects the February acquisition of BD's Biosciences and Diagnostic Solutions businesses. The more telling number is legacy organic growth of 10% in constant currency, up from 9% in the second quarter. Waters also raised full-year guidance for the fourth straight quarter. The central tension is that the legacy franchise is accelerating while the acquired businesses, cash conversion and near-term earnings growth still lag. The headline beat leans heavily on the core Waters engine.
The acquisition dominates the reported figures. Organic revenue rose to $871 million from $800 million. The acquired businesses contributed $896 million, only 1% above the $885 million prior-year comparable, a slowdown from 4% growth in the second quarter. GAAP EPS fell to $0.82 from $2.50, weighed down by $323 million of purchased-intangibles amortization and inventory step-ups plus integration and restructuring costs. On an adjusted basis, profitability rebounded sharply. Operating margin reached 30.1%, up from 25% in the second quarter and roughly in line with legacy Waters' 30.3% a year ago. Cost actions drove the improvement, and run-rate savings hit $200 million more than two years ahead of schedule.
The call showed broad momentum in the legacy business. Chemistry consumables grew 12% in constant currency, the sixth straight double-digit quarter. LC-MS instruments improved about 200 basis points to 10-11%, helped by replacement cycles, GLP-1 work, PFAS testing and India generics. Clinical mass spec rose 18%, and legacy China grew more than 20%. On the acquired side, flow reagents accelerated 400 basis points to 8%. Biosciences China returned to growth for the first time in 10 quarters, and BD net price realization climbed from a historical 50 basis points to 120. The soft spots were real, however. Molecular diagnostics and point of care fell 6% on channel inventory reduction and lighter respiratory testing, and China microbiology dropped more than 20% on DRG reimbursement pressure. Management characterized the acquired-business slowdown as planned, and the implied second-half constant-currency growth rate for those businesses is about 5%.
The forward story widened. Waters acquired MOBILion Systems, whose SLIM ion mobility technology gives the company an entry into a roughly $2.2 billion discovery proteomics market. Management also cited:
- HPV self-collection partnerships with Quest and LabCorp, with revenue beginning in 2027;
- dozens of new AI-native biotech customers;
- double-digit millions of reshoring-related orders already received.
The initial 2027 framework calls for mid-single-digit-plus organic growth, with a high-single-digit aspiration. It also targets 100 basis points of margin expansion to 29.2% and low-teens EPS growth. That margin target must absorb a roughly 70-basis-point headwind from adding back the first six weeks of BD costs.
Bears have legitimate ammunition on cash and near-term earnings. Free cash flow fell to $68 million from $202 million in the second quarter. Management attributed the drop to about $240 million of receivables and SAP-migration timing items plus $81 million of integration costs. Inventory sits near 160 days, against legacy Waters' 110-day target. Fourth-quarter guidance calls for revenue of $1.801-$1.819 billion but adjusted EPS of just $4.58-$4.68, only 1% to 3% growth. The quarter has four fewer selling days and requires a 14% sequential revenue step-up. The full-year EPS raise to $14.60-$14.70 was modest next to the $43 million revenue increase because of reinvestment.
Investors had largely positioned for strength. Sentiment moved from slightly negative (-0.06) to modestly positive (+0.13), a meaningful but not euphoric shift. Shares rose 17.3% from the open after the August report to $449.53. That leaves the stock about 21.5% above its 200-day moving average and 18.5% above its inter-earnings low. Shares entered the report 6.8% below the 52-week high of $482.28 set October 28, so some of the run-up had already been given back. The Earnings Whispers trend readings are uniformly positive, consistent with a stock that has been rewarded for steady guidance increases.
The bottom line is that Waters produced a high-quality legacy quarter and a credible 2027 setup, but it met elevated expectations rather than surpassing them. Accelerating organic growth, expanding margins, rising BD pricing and early synergy delivery support the thesis. Still, a 1% acquired-business growth rate, weak free cash flow, bloated inventory and nearly flat fourth-quarter EPS growth mean the integration case remains a work in progress. With the stock well above its long-term average, execution on the Q4 ramp and on cash conversion now matters more than another headline beat.